June 18 (Reuters) - Clinical-stage biotech Kardigan raised $400 million in an upsized initial public offering on Wednesday, after pricing shares at the top of its target range, joining a wave of companies seeking the public markets.

Here are more details:

• The Princeton, New ​Jersey-based company sold 25 million shares priced at $16 per share. It had intended to price its shares between $14 and $16 each.

• Activity in the U.S. IPO market has rebounded, with companies from several sectors racing to go public as investor enthusiasm for fresh stocks remains strong.

• The company is set to debut on Nasdaq on Thursday under the ticker symbol "KARD".

• J.P. Morgan, Jefferies, Leerink Partners and TD Cowen ​are the underwriters for the offering.

• The company is advancing three late-stage experimental therapies: danicamtiv for genetic dilated cardiomyopathy, ​ataciguat for calcific aortic ​valve stenosis, and ⁠tonlamarsen targeting hepatic angiotensinogen for blood pressure management in acute severe hypertension.

• Kardigan plans to use the proceeds from the offering, along ​with existing cash, to fund clinical development of the three drugs, ​as well ⁠as for other research activities, working capital and general corporate purposes.